Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial.

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

The findings may also help explain why reducing methylation, which is what the new IDH inhibitor vorasidenib does, only works early in the disease. Later in the disease, other genetic drivers that ...